CIK 0000818686
- Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 39148213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-14 | Codner Iris Beck EVP Global Brand&Communication | Option exercise · Restricted Share Units | −3,212 | 6,425 | ||
| 2019-02-13 | de Notaristefani Carlo Executive VP Global Operations | Sale | −5,041 | $17.88 | $90K | 12,120.73 |
| 2019-02-12 | de Notaristefani Carlo Executive VP Global Operations | Grant or award | +14,432 | 17,161.73 | ||
| 2019-02-12 | de Notaristefani Carlo Executive VP Global Operations | Grant or award · Restricted Share Units | +1,204 | 1,204 | ||
| 2019-02-12 | Codner Iris Beck EVP Global Brand&Communication | Grant or award | +6,494 | 14,784.04 | ||
| 2019-02-12 | Sabag Mark EVP, Global Human Resources | Grant or award | +9,381 | 50,897.54 | ||
| 2019-01-02 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −1,643 | $15.70 | $26K | 11,825.51 |
| 2018-12-31 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +4,640 | 13,468.51 | ||
| 2018-12-31 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −4,640 | 4,640 | ||
| 2018-11-30 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +2,711 | 9,761.51 | ||
| 2018-11-30 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −933 | $21.76 | $20K | 8,828.51 |
| 2018-11-30 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −2,711 | 8,133 | ||
| 2018-11-05 | McClellan Michael James EVP, Chief Financial Officer | Option exercise | +695 | 11,990.27 | ||
| 2018-11-05 | McClellan Michael James EVP, Chief Financial Officer | Sale | −346 | $22.73 | $8K | 11,644.27 |
| 2018-11-05 | McClellan Michael James EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −695 | 695 | ||
| 2018-09-18 | O'Grady Brendan P. EVP, North America Commercial | Option exercise | +1,241 | 2,629.49 | ||
| 2018-09-18 | O'Grady Brendan P. EVP, North America Commercial | Sale | −1,241 | $23.71 | $29K | 1,388.49 |
| 2018-09-18 | O'Grady Brendan P. EVP, North America Commercial | Option exercise · Restricted Share Units | −1,241 | 1,241 | ||
| 2018-09-18 | Nazzi Gianfranco EVP, Growth Markets Commercial | Option exercise | +2,638 | 8,384.36 | ||
| 2018-09-18 | Nazzi Gianfranco EVP, Growth Markets Commercial | Sale | −1,379 | $23.69 | $33K | 7,005.36 |
Page 69 of 76 · 1,517 trades